Oncotarget

Researchers discuss the use of biomarkers in predicting response to paclitaxel in cancer therapy, emphasizing personalized medicine. They explore the SSR3 gene as a potential biomarker for paclitaxel susceptibility in cancer cells, highlighting its role in the unfolded protein response pathway and challenges in treating glioblastoma.

Researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, and Jennifer K. Litton discuss the feasibility and outcomes of using dual checkpoint inhibition with durvalumab and tremelimumab in HR+/HER2-negative breast cancer patients before surgery. The study showed mixed responses among patients, revealing both benefits and challenges of this treatment approach.

Researchers discuss the synergistic effects of ABT199/venetoclax and thiotepa in AML cells, showcasing enhanced apoptosis activation and DNA damage response. The combination shows promise in overcoming drug resistance and reducing pro-survival proteins in leukemia treatment.

Researchers discuss the analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay. The assay accurately identifies tumor-specific variants for treatment monitoring and recurrence detection using whole genome sequencing.

Dr. Blagosklonny discusses the drawbacks of osimertinib in lung cancer treatment and proposes preemptive combinations to increase PFS without harm. The podcast delves into the effectiveness of different combinations for EGFR mutant lung cancer and MET-driven lung cancer.

Researchers from various institutions discuss the G-quadruplex landscape and its regulation in DNA, challenging conventional beliefs. They explore a new antibody capture method to study G4s without bias, shedding light on their distribution and regulation in the genome.

Researcher Thomas M. Cardillo discusses the synergistic anti-tumor effects of Sacituzumab Govitecan with platinum-based chemotherapy in inhibiting cancer cell growth. They explore significant tumor regressions in mice tumor models, showing promise for clinical investigation in solid tumor treatment revolution.

Exploring Impact Journals and Onco Target at AACR Annual Meeting 2024: Discussion on the dedication of Impact Journals to publishing scholarly works in biomedical sciences, focusing on cancer and aging research. Highlighting their participation at AACR, emphasizing insightful peer review and interdisciplinary collaboration in oncology and biomedical fields.

Researchers investigate GZ17-6.02 compound in killing multiple myeloma cells. Study shows efficacy against inhibitor-resistant cells. Synergistic effects with proteasome inhibitors on key cell death pathways. Podcast explores potential of GZ17-6.02 in cancer treatment.

Researchers discuss the significant antitumor effects of combining Sacituzumab govitecan with platinum-based chemotherapy in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Promising results are seen in mouse models with this combination treatment.